These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 10065098)

  • 1. [A study of the safety of rapid infusion of alendronate].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y
    Gan To Kagaku Ryoho; 1999 Feb; 26(3):345-51. PubMed ID: 10065098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Study on the safety of rapid infusion and the efficacy of incadronate against bone metastasis of breast cancer].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1623-8. PubMed ID: 10553421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased renal calcium reabsorption by parathyroid hormone-related protein is a causative factor in the development of humoral hypercalcemia of malignancy refractory to osteoclastic bone resorption inhibitors.
    Onuma E; Azuma Y; Saito H; Tsunenari T; Watanabe T; Hirabayashi M; Sato K; Yamada-Okabe H; Ogata E
    Clin Cancer Res; 2005 Jun; 11(11):4198-203. PubMed ID: 15930357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Breast cancer with osteoblastic bone metastasis treated successfully with bisphosphonate: a case report].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y
    Gan To Kagaku Ryoho; 1999 Oct; 26(11):1651-5. PubMed ID: 10553426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pain relief with alendronate therapy in a breast cancer patient with bone metastasis].
    Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y; Naito Y
    Gan To Kagaku Ryoho; 2000 Apr; 27(4):633-7. PubMed ID: 10791010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bisphosphonates for cancer patients: why, how, and when?
    Body JJ; Mancini I
    Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Weekly paclitaxel therapy for metastatic breast cancer].
    Kokufu I; Taniguchi H; Kimura F; Fukuda K; Yamamoto M; Yano T; Yamada K
    Gan To Kagaku Ryoho; 2002 Feb; 29(2):221-6. PubMed ID: 11865627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and pain palliation of zoledronic acid in patients with breast cancer, prostate cancer, or multiple myeloma who previously received bisphosphonate therapy.
    Vogel CL; Yanagihara RH; Wood AJ; Schnell FM; Henderson C; Kaplan BH; Purdy MH; Orlowski R; Decker JL; Lacerna L; Hohneker JA
    Oncologist; 2004; 9(6):687-95. PubMed ID: 15561812
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis.
    Guañabens N; Parés A; Ros I; Alvarez L; Pons F; Caballería L; Monegal A; Martínez de Osaba MJ; Roca M; Peris P; Rodés J
    Am J Gastroenterol; 2003 Oct; 98(10):2268-74. PubMed ID: 14572578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of zoledronic acid rapid infusion in lung cancer patients with bone metastases: a single institution experience.
    Kotteas E; Alamara C; Kiagia M; Pantazopoulos K; Boufas A; Provata A; Charpidou A; Syrigos KN
    Anticancer Res; 2008; 28(1B):529-33. PubMed ID: 18383897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of a rapid (2-h) versus a slow (24-h) infusion of alendronate in the treatment of hypercalcemia of malignancy.
    Zysset E; Ammann P; Jenzer A; Gertz BJ; Portmann L; Rizzoli R; Jaquet-Müller F; Pryor-Tillotson S; Bonjour JP; Burckhardt P
    Bone Miner; 1992 Sep; 18(3):237-49. PubMed ID: 1392697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single zoledronic acid infusion reduces bone resorption markers more rapidly than weekly oral alendronate in postmenopausal women with low bone mineral density.
    Saag K; Lindsay R; Kriegman A; Beamer E; Zhou W
    Bone; 2007 May; 40(5):1238-43. PubMed ID: 17347063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer.
    Chan S; Scheulen ME; Johnston S; Mross K; Cardoso F; Dittrich C; Eiermann W; Hess D; Morant R; Semiglazov V; Borner M; Salzberg M; Ostapenko V; Illiger HJ; Behringer D; Bardy-Bouxin N; Boni J; Kong S; Cincotta M; Moore L
    J Clin Oncol; 2005 Aug; 23(23):5314-22. PubMed ID: 15955899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-naïve patients with locally advanced or metastatic breast carcinoma.
    Hsu C; Huang CS; Chao TY; Lu YS; Bu CF; Chen MM; Chang KJ; Cheng AL
    Cancer; 2002 Nov; 95(10):2044-50. PubMed ID: 12412156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases.
    Body JJ; Greipp P; Coleman RE; Facon T; Geurs F; Fermand JP; Harousseau JL; Lipton A; Mariette X; Williams CD; Nakanishi A; Holloway D; Martin SW; Dunstan CR; Bekker PJ
    Cancer; 2003 Feb; 97(3 Suppl):887-92. PubMed ID: 12548591
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypocalcemia associated with metastatic bone disease. A retrospective study.
    Raskin P; McClain CJ; Medsger TA
    Arch Intern Med; 1973 Oct; 132(4):539-43. PubMed ID: 4742409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.